-
Medical journals
- Career
Heart Failure
We recommend
Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
26. 7. 2022 Source: Heart FailureIn a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.
No content is currently available on this topic.LoginSubscribe
E-courses on this topic
Course detailAuthors: MUDr. Sylvie Štrégl Hrušková, prof. MUDr. Michal Vrablík, Ph.D., prof. MUDr. Vojtěch Melenovský, CSc., MUDr. Marie Lazárová
Conferences news
Go to records
Most read on this topic
Journal on this topic
Related topicLogin#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career